SEC EDGARJUN 52 min read$QURE

Kaye Jack sold $79K of QURE

Kaye Jack sold 2,645 shares of uniQure N.V. (QURE) at $30.01 on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Kaye Jack

Published Jun 5, 2026, 8:43 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 5, 2026, 8:48 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$QURE

Neutral

medium confidence

Mentioned

$QURE

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$QURENeutralLow

Why it matters

The disclosure provides a datapoint on director selling activity, but it is not a new operational or clinical milestone.

Market read

Traders may monitor for broader insider activity, but this specific filing alone is unlikely to drive a sustained repricing.

What to watch

The filing does not disclose intent beyond the plan; without follow-on buying/selling patterns or size relative to holdings, signal strength is limited.

Relevance 6/10Novelty 6/10Timing: Filed today; sale executed 2026-06-03.

Background

This is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$QURENeutralMedium confidence

Context

Director Kaye Jack filed an open-market sale of 2,645 QURE shares at $30.01 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is a routine insider transaction under a pre-arranged 10b5-1 plan, with no accompanying corporate event or new company-specific catalyst.

Market effects

Sector

Minimal—single insider sale in a biotech does not reset sector expectations.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

issuer
uniQure N.V.
Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.
insider
Kaye Jack
Director who executed the open-market sale disclosed in the filing.
trading mechanism
10b5-1 plan
Pre-arranged plan that typically reduces the informational content of insider trades.

Read at source ← All news

OCT 8

$QUREHighAI 9/10

Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA Filing Clarity?

uniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.

simplywall.st2 min

OCT 7

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min

OCT 5

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

marketscreener.com1 min

OCT 5

$QUREMed

QURE Downgraded by Barclays -- Price Target Lowered to $28.00

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

gurufocus.com2 min

OCT 2

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min

OCT 1

$QUREHighAI 8/10

uniQure (QURE) Reports New AMT 130 Data As FDA Opens Accelerated Review Path

uniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.